会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • PERCUTANEOUS TULOBUTEROL PREPARATION AND PROCESS FOR PRODUCING THE SAME
    • 胰岛素的制备方法及其制备方法
    • WO1997014411A1
    • 1997-04-24
    • PCT/JP1996002422
    • 1996-08-28
    • NITTO DENKO CORPORATIONHOKURIKU SEIYAKU CO., LTD.NAKAGAWA, TakeakiNAKANO, YoshihisaOTSUKA, Saburo
    • NITTO DENKO CORPORATIONHOKURIKU SEIYAKU CO., LTD.
    • A61K31/135
    • A61K9/7053A61K9/7076A61K31/137
    • A percutaneous tulobuterol preparation obtained by laminating a pressure-sensitive adhesive layer comprising as the main component a synthetic rubber containing micro-crystalline tulobuterol of 2 to 20 mu m in average particle size onto a support; in particular, a percutaneous tulobuterol preparation wherein the micro-crystalline tulobuterol is one obtained by dissolving tulobuterol and a pressure-sensitive adhesive comprising as the main component a synthetic resin in a good solvent followed by recrystallization; and a process for producing the preparation which comprises homogeneously dissolving the adhesive and tulobuterol in a good solvent, applying the resulting adhesive solution onto one face of a peelable film and drying to thereby form an adhesive layer; then laminating the adhesive layer onto a support; and recrystallizing tulobuterol at 10 to 30 DEG C to thereby give an adhesive layer wherein microcrystals of 2 to 20 mu m in average particle size have been homogeneously dispersed. The preparation is excellent in the long-lasting drug effect. The above process makes it possible to efficiently produce the preparation.
    • 通过将包含作为主要成分的含有平均粒径为2〜20μm的微晶杜洛特罗的合成橡胶的压敏粘合剂层层压到载体上而获得的经皮珠杜特醇制剂; 特别是一种经皮十四指醇制剂,其中微结晶丁特罗是通过将妥洛特罗和包含合成树脂作为主要成分的压敏粘合剂溶解在良溶剂中,随后重结晶得到的那种; 以及制备该制剂的方法,该方法包括将粘合剂和十四指醇均匀地溶解在良溶剂中,将所得粘合剂溶液施加到可剥离膜的一个表面上并干燥从而形成粘合剂层; 然后将粘合剂层层压到载体上; 并在10〜30℃下重结晶十四指醇,得到平均粒径为2〜20μm的微晶均匀分散的粘合剂层。 该制剂具有优异的长效药物作用。 上述方法使得可以有效地制备该制剂。
    • 6. 发明申请
    • PERCUTANEOUS PREPARATIONS
    • PERCUTANEOUS准备
    • WO1998013035A1
    • 1998-04-02
    • PCT/JP1997003412
    • 1997-09-25
    • NITTO DENKO CORPORATIONHOKURIKU SEIYAKU CO., LTD.NAKANO, YoshihisaYAMAMOTO, KeijiNAKAGAWA, TakeakiHORI, MitsuhikoOTSUKA, Saburo
    • NITTO DENKO CORPORATIONHOKURIKU SEIYAKU CO., LTD.
    • A61K31/135
    • A61K9/7061A61K31/137
    • Percutaneous preparations composed of a support and a plaster layer located on one face thereof and containing 2-tert-butylamino-1-(2-chloro-4-hydroxy-phenyl)ethan-1-o1 or its pharmacologically acceptable salt and a pressure-sensitive adhesive, wherein the adhesive is an acrylic polymer substantially free from carboxy or comprises a material containing at least one high-molecular-weight rubber component with an average molecular weight of from 300,000 to 2,500,000 and at least one additive selected from among C12-18 fatty acid esters, C8-10 fatty acid monoglycerides and C6-10 dibasic acid esters. These percutaneous preparations are excellent in percutaneous drug-absorption properties, can give long-lasting drug effects with little side effect and, therefore, are useful in the prevention and treatment of threatened abortion, premature birth, urination disorders such as urinary incontinence, etc.
    • 含有2-叔丁基氨基-1-(2-氯-4-羟基 - 苯基)乙-1-醇或其药理学上可接受的盐和压敏粘合剂的经皮制剂由载体和石膏层组成, 其中所述粘合剂是基本上不含羧基的丙烯酸聚合物,或包含含有至少一种平均分子量为300,000至2,500,000的高分子量橡胶组分的材料和至少一种选自C12-18的添加剂 脂肪酸酯,C8-10脂肪酸单甘油酯和C6-10二元酸酯。 这些经皮制剂经皮药物吸收性优异,可以产生持久的药物作用,副作用小,因此可用于预防和治疗威胁性流产,早产,排尿障碍如尿失禁等。